Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors

Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKI) are recommended first-line therapy for advanced non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. It is of clinical interest to identify concurrent genetic mutations in NSCLC patients with EGFR mutations in the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Chang, Shih-Chieh, Lai, Yi-Chun, Chang, Cheng-Yu, Huang, Li-Kuo, Chen, Shu-Jen, Tan, Kien Thiam, Yu, Pei-Ning, Lai, Jiun-I
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2019
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700434/
https://ncbi.nlm.nih.gov/pubmed/31401335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.07.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados